CBU
FATE icon

CIBC Bancorp USA’s Fate Therapeutics FATE Stock Holding History

CIBC Bancorp USA’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$14.6K Buy
+11,593
New +$12.5K ﹤0.01% 1463

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wilshire Advisors Santa Monica, California $10.3M AUM 79.91% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

CIBC Bancorp USA's FATE Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Fate Therapeutics (FATE) in Q3 2025: 11,593 shares worth $14.6K. The stake represents ﹤0.01% of the portfolio and ranks #1463 among its holdings.

143 funds tracked by Wall St. Rank hold FATE as of Q3 2025.

  • CIBC Bancorp USA held 11,593 shares of Fate Therapeutics worth $14.6K as of Q3 2025.
  • Fate Therapeutics was a new CIBC Bancorp USA position in Q3 2025.
  • Fate Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1463 holding.
  • 143 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.